How PR is released and disseminated are 2 different things.The statement below is the first part of my post on the fact the lawsuit continues,but press with Amylin has always been weak.Witness a dozen or so examples from the recent News on the juvenile diabetes deal,or pancreatic,Amylin ALWAYS does it poorly,as opposed to Novo who,using the pancreatic example PR and wrote about the issue being overblown.I agree this is a ploy by those covering,but lends credence to the fact that Amylin are novices in pharma. ---------------------------------
Amylin continues to believe that Lilly's conduct violates our diabetes collaboration agreements, is anti-competitive and limits patients' treatment options. It is important to note that the Court's decision did not make any findings on the merits of our claims, but merely declines to award injunctive relief, based on the conclusion that monetary damages would be sufficient. We intend to vigorously pursue the litigation to enforce our legal and contractual rights."
The complete order is being filed on Amylin's Current Report on Form 8-K with the Securities and Exchange Commission.
This is the part of Amylins press release thats going to stick:
In 2002, Amylin entered an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type 2 diabetes that is currently marketed as BYETTA® (exenatide) injection. Exenatide is also the active ingredient in BYDUREON(TM) (exenatide extended-release for injectable suspension), a once-weekly version currently under review by the FDA.
"a first line treatment for type 2 diabetes" not bundled with a lot of other choices!!! Amylin is in a strong position given this statement on the partnership...
I still stand on my opinion posted last night that Amylin will be in the green today.......
"Lilly Wins Versus Amylin Over Diabetes Drug Marketing" -Eli Lilly won a ruling in a lawsuit brought by Amylin Pharmaceuticals, Inc. "The latter company sought to prevent Lilly from using the same sales force to sell Amylin's diabetes drug and that of a competitor." ________________________